Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic

Absorption and transport properties of a codfish-derived peptide and its protective effect on bone loss in ovariectomized mice

“…2 Currently, the main medications for the treatment of osteoporosis are anti-resorptive drugs and anabolic agents, including oral bisphosphonates, selective estrogen receptor modulators, intravenous bisphosphonates, teriparatide, and denosumab. 3 These medications could effectively reduce the incidence of fractures in individuals with osteoporosis. However, studies have shown that long-term use of estrogen replacement therapy increases the risk of coronary heart disease and ovarian cancer, bisphosphonate use can cause severe hypocalcemia in patients with impaired renal function, and rare atypical femoral fractures and osteonecrosis of the jaw may occur with denosumab treatment.…”